@article{06b351269db74c64ba2286df0e45861c,
title = "NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria",
abstract = "Summary Nuclear factor κB (NF-κB), a key activator of inflammation, primes the NLRP3-inflammasome for activation by inducing pro-IL-1β and NLRP3 expression. NF-κB, however, also prevents excessive inflammation and restrains NLRP3-inflammasome activation through a poorly defined mechanism. We now show that NF-κB exerts its anti-inflammatory activity by inducing delayed accumulation of the autophagy receptor p62/SQSTM1. External NLRP3-activating stimuli trigger a form of mitochondrial (mt) damage that is caspase-1- and NLRP3-independent and causes release of direct NLRP3-inflammasome activators, including mtDNA and mtROS. Damaged mitochondria undergo Parkin-dependent ubiquitin conjugation and are specifically recognized by p62, which induces their mitophagic clearance. Macrophage-specific p62 ablation causes pronounced accumulation of damaged mitochondria and excessive IL-1β-dependent inflammation, enhancing macrophage death. Therefore, the {"}NF-κB-p62-mitophagy{"} pathway is a macrophage-intrinsic regulatory loop through which NF-κB restrains its own inflammation-promoting activity and orchestrates a self-limiting host response that maintains homeostasis and favors tissue repair.",
author = "Zhenyu Zhong and Atsushi Umemura and Elsa Sanchez-Lopez and Shuang Liang and Shabnam Shalapour and Jerry Wong and Feng He and Daniela Boassa and Guy Perkins and Ali, {Syed Raza} and McGeough, {Matthew D.} and Ellisman, {Mark H.} and Ekihiro Seki and Gustafsson, {Asa B.} and Hoffman, {Hal M.} and Diaz-Meco, {Maria T.} and Jorge Moscat and Michael Karin",
note = "Funding Information: We thank M.K. lab members for helpful discussions and eBioscience, Cell Signaling Technologies, Santa Cruz Technologies, and Life Technologies for gifts of antibodies and other reagents. Z.Z. was supported by Cancer Research Institute (CRI) Irvington postdoctoral fellowship; A.U. was supported by JSPS KAKENHI (15H06547), Kanae Foundation for the Promotion of Medical Science, and a Global Grant Scholarship from The Rotary Foundation; E.S.-L. was supported by Sara Borrell fellowship under ISCIII/MICINN program; S.S. was supported by fellowships from CRI-Irvington and German Research Foundation (SH721/1-1); and J.W. was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research (MFE-135425). Research was supported by grants from the NIH (AI043477 and CA163798) to M.K., (GM103412) to M.H.E. for support of the National Center for Microscopy and Imaging Research, (AA020172 and DK085252) to E.S., (ES010337) to M.K. and E.S., (HL087023) to A.B.G., (AI52430) to H.M.H., (CA192642) to M.T.D.-M., (CA030199) to M.T.D-M. and J.M., (CA132847, CA172025) to J.M., Leukemia and Lymphoma Society SCOR (20132569) to Tom Kipps and M.K., and the Alliance for Lupus Research (257214) to M.K., who is an American Cancer Research Professor and holds the Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",
year = "2016",
month = feb,
day = "25",
doi = "10.1016/j.cell.2015.12.057",
language = "English (US)",
volume = "164",
pages = "896--910",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "5",
}